Literature DB >> 35027336

Coagulome and the tumor microenvironment: an actionable interplay.

Antoine Galmiche1, Janusz Rak2, Lubka T Roumenina3, Zuzana Saidak4.   

Abstract

Human tumors often trigger a hypercoagulable state that promotes hemostatic complications, including venous thromboembolism. The recent application of systems biology to the study of the coagulome highlighted its link to shaping the tumor microenvironment (TME), both within and outside of the vascular space. Addressing this link provides the opportunity to revisit the significance of biomarkers of hemostasis and assess the communication between vasculature and tumor parenchyma, an important topic considering the advent of immune checkpoint inhibitors and vascular normalization strategies. Understanding how the coagulome and TME influence each other offers exciting new prospects for predicting hemostatic complications and boosting the effectiveness of cancer treatment.
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  anticoagulants; biomarkers; coagulome; tumor microenvironment; venous thromboembolism

Mesh:

Substances:

Year:  2022        PMID: 35027336     DOI: 10.1016/j.trecan.2021.12.008

Source DB:  PubMed          Journal:  Trends Cancer        ISSN: 2405-8025


  3 in total

1.  Regulation of Tissue Factor by CD44 Supports Coagulant Activity in Breast Tumor Cells.

Authors:  Amélie V Villard; Anthony Genna; Justine Lambert; Marianna Volpert; Agnès Noël; Brett Hollier; Myriam Polette; Aline M Vanwynsberghe; Christine Gilles
Journal:  Cancers (Basel)       Date:  2022-07-05       Impact factor: 6.575

Review 2.  Therapeutic Strategies Focused on Cancer-Associated Hypercoagulation for Ovarian Clear Cell Carcinoma.

Authors:  Ryo Tamura; Kosuke Yoshihara; Takayuki Enomoto
Journal:  Cancers (Basel)       Date:  2022-04-24       Impact factor: 6.575

3.  Targeting coagulation to unlock antitumor immunity?

Authors:  Antoine Galmiche; Zuzana Saidak; François Ghiringhelli
Journal:  Oncoimmunology       Date:  2022-02-24       Impact factor: 8.110

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.